Dr. Brian Lawenda discusses the use of genomic testing of the prostate cancer tissue. The information derived from these tests (such as Prolaris, OncotypeDx, Decipher) assesses whether the tumor tissue has a genetic profile suggesting that it is more or less aggressive than the clinical risk group (low, intermediate or high-risk). This can be helpful for patients who are not certain if they want to pursue an active surveillance or more aggressive management plan (prostatectomy or radiation therapy).
